> ## Content Index
> Fetch the complete content index at: https://www.pharmamanufacturingiq.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Concept Life Sciences appoints chief commercial officer
- URL: https://www.pharmamanufacturingiq.com/concept-life-sciences-appoints-chief-commercial-officer/
- Published: 2026-11-10T14:00:00.000Z
- Updated: 2026-11-10T14:00:01.000Z
- Author: Olivia Friett
- Tags: People & Appointments

**Concept Life Sciences, a contract research organisation (CRO) has appointed Dean Bornilla as chief commercial officer (CCO) to spearhead its international growth strategy, with a focus on expanding its presence in North America and Europe.**

The appointment brings more than 25 years of life sciences commercial leadership experience to Concept as the company looks to strengthen its position in key global markets, deepen strategic customer relationships and broaden access to its specialist scientific capabilities.

Bornilla joins the company following senior commercial leadership roles at Pace Life Sciences, Selvita and Curia (formerly AMRI), where he led commercial growth initiatives, international market expansion and strategic customer development across the CRO, CDMO and pharmaceutical sectors.

As chief commercial officer, Bornilla will lead the company's global commercial operations, including sales, business development, marketing and strategic account management. A key priority will be connecting pharmaceutical, biotechnology and wider scientific organisations with Concept's integrated scientific services, helping customers address increasingly complex research and development challenges.

Dean Bornilla, chief commercial officer of Concept Life Sciences, said:  
"Concept Life Sciences has an impressive breadth of scientific expertise and a strong reputation for helping customers solve complex challenges. What attracted me to the business is the opportunity to build on those strengths and bring its capabilities to a wider international customer base. Our differentiated capabilities across drug discovery and development, material sciences, and safety toxicology position us to address a broad range of increasingly complex scientific challenges.

"My priority will be to strengthen our commercial organisation, deepen relationships with existing customers and open new opportunities in North America, Europe and other strategic markets. By connecting customers with the right expertise across our portfolio, we can support their innovation goals while delivering sustainable growth for the business."